Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacy.

Wyman K, Atkins MB, Prieto V, Eton O, McDermott DF, Hubbard F, Byrnes C, Sanders K, Sosman JA
Cancer. 2006 106 (9): 2005-11

PMID: 16565971 · DOI:10.1002/cncr.21834

MeSH Terms (18)

Adult Aged Aged, 80 and over Antineoplastic Agents Benzamides Female Humans Imatinib Mesylate Immunohistochemistry Male Melanoma Middle Aged Piperazines Protein Kinase Inhibitors Proto-Oncogene Proteins c-kit Pyrimidines Receptor, Platelet-Derived Growth Factor alpha Receptor, Platelet-Derived Growth Factor beta

Connections (1)

This publication is referenced by other Labnodes entities: